Creat Sens secured EUR 125k from Banco Sabadell's BStartup Health and Genesis Ventures

CreatSens, a Tarragona, Spain-based company manufacturing a non-invasive device that allows to control and detect chronic kidney diseases through a simple drop of blood, announced that it completed an investment round of € 125,000 ($140k).

The money was provided by Banco Sabadell's BStartup Health and Genesis Ventures, a Barcelona-based fund managed by Genesis Biomed,

The capital investment allows the company to develop its prototype for the diagnosis of chronic kidney disease, which will be validated next year through. clinical trials.

CreatSens, founded in September 2017 by Adrià Maceira, Francisco Javier Andrade, Marta Novell, Tomàs Guinovart and Pascal Blondeau, is a spin-off of the Universitat Rovira and Virgili. The company works to monitor the progress of chronic kidney disease through state-of-the-art technological tools that measure patient-relevant parameters. much simpler form to the present one. His product focuses on the creation of a paper medical device capable of measuring creatinine and potassium levels, two key biomarkers in the development of this disease, through a drop of blood.